HomeInsightsDividend

Sun Pharma Advanced Research Company Ltd dividend

Sun Pharma Advanced Research Company Ltd dividend

download
stocks purchased

₹ 1.3 Cr

Volume transacted

stocks purchased

57.6 K

stocks traded

Last Updated time: 23 Jul 15:01 PM

Image

Sun Pharma Advanced Research Company Ltd

NSE: SPARC

DPS

--

Last updated : FY 2024

Key Highlights

    The Dividend per Share of Sun Pharma Advanced Research Company Ltd is ₹ 0 as of 2024 .a1#The Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2019 to 0 % on March 2024 . This represents a CAGR of 0.0% over 6 years. a1#The Latest Trading Price of Sun Pharma Advanced Research Company Ltd is ₹ 222 as of 23 Jul 14:53 .a1#The Market Cap of Sun Pharma Advanced Research Company Ltd changed from ₹ 5823 crore on March 2023 to ₹ 12005 crore on March 2024 . This represents a CAGR of 43.58% over 2 years. a1#The Revenue of Sun Pharma Advanced Research Company Ltd changed from ₹ 58.42 crore to ₹ 20.96 crore over 5 quarters. This represents a CAGR of -55.96% a1#The EBITDA of Sun Pharma Advanced Research Company Ltd changed from ₹ -78.84 crore to ₹ -101 crore over 5 quarters. This represents a CAGR of 22.33% a1#The Net Pr of Sun Pharma Advanced Research Company Ltd changed from ₹ -81.99 crore to ₹ -105 crore over 5 quarters. This represents a CAGR of 22.62% a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

Share Price Vs Dividend Yield

swot
swot

Company Fundamentals For Sun Pharma Advanced Research Company Ltd

Market Cap

7,266 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

57.8

DTE *

0.5

ROE *

-307.9

ROCE *

-130.8

Dividend Yield *

0

DPS *

0

Dividend Payout *

0

Ann.Dividend % *

0

* All values are consolidated

Last Updated time: 23 Jul 15:01 PM

* All values are consolidated

Last Updated time: 23 Jul 15:01 PM

×

Historical Dividend Payout of Sun Pharma Advanced Research Company Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Sun Pharma Advanced Research Company Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230
Mar '240

* All values are a in %

Dividend per Share (DPS) Over Time

×

DIVIDENDYIELD

Dividend Yield is a financial ratio that shows the annual dividend income relative to the market price of a share. It is calculated by dividing the dividend per share by the current market price per share, expressed as a percentage.

Dividend Yield Comparison With Top Peers

1M

1Y

3Y

5Y

* All values are in %

Net Profit Vs Dividend Per Share

Image

Sun Pharma Advanced Research Company Ltd

NSE: SPARC

PRICE

222

-1.90 (-0.85%)

stock direction

Last updated : 23 Jul 14:53

SWOT Analysis Of Sun Pharma Advanced Research Company Ltd

Strength

1

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

Overview of Dividend

Types of Dividend


Special Dividend

A dividend is paid on common stock when a company has accumulated substantial profits over years, often seen as excess cash that doesn't need immediate use.


Preferred Dividend

A quarterly dividend is paid to preferred stock owners, typically accumulating a fixed amount, and is earned on shares that function more like bonds.


Interim Dividend

Companies declare interim dividends before final full-year accounts are prepared, specifically in India, during the financial year from April to March of the following year.


Final Dividend

A final dividend is issued after the year's accounts have been compiled. Aside from this, the following list highlights the most prevalent sorts of dividends:


×

Historical Market Cap of Sun Pharma Advanced Research Company Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Sun Pharma Advanced Research Company Ltd

Period
Mar '235824
Mar '2412006

* All values are a in crore

×

Historical Revenue of Sun Pharma Advanced Research Company Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Sun Pharma Advanced Research Company Ltd

Period
Mar '2358
Jun '2334
Sep '2330
Dec '2320
Mar '2421

* All values are a in crore

×

Historical EBITDA of Sun Pharma Advanced Research Company Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Sun Pharma Advanced Research Company Ltd

Period
Mar '23-79
Jun '23-92
Sep '23-83
Dec '23-96
Mar '24-101

* All values are a in crore

×

Historical Net Profit of Sun Pharma Advanced Research Company Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Sun Pharma Advanced Research Company Ltd

Period
Mar '23-82
Jun '23-95
Sep '23-86
Dec '23-100
Mar '24-106

* All values are a in crore

About Sun Pharma Advanced Research Company Ltd

About Sun Pharma Advanced Research Company Ltd

    Sun Pharma Advanced Research Company Ltd. (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems. The Company works on innovation and new product development for global markets. They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Ltd was incorporated on March 1, 2006 as an innovative and development company. They commenced operations on March 22, 2006. As per Scheme of Arrangement, all assets and liabilities of the Innovative Research & Development business including Novel Drug Delivery System (NDDS) division of Sun Pharmaceuticals Industries' Research & Development undertaking stands transferred and vested in the Company with effect from Appointed date on February 28, 2007. The demerger became effective on March 28, 2007. On Scheme being effective, the Company ceased to be subsidiary of Sun Pharmaceutical Industries Ltd., and the demerged Company. During the year 2009-10, the Department of Scientific and Industrial Research (DSIR), Government of India sanctioned a 15 year unsecured soft loan under their Drug and Pharmaceutical Research Programme for a project of the Company. During 2011, the Company announced USFDA approval for DOCEFREZ (docetaxel) for Injection'. During 2014, the Company announced Govt. of India approval for Paclitaxel Injection Concentrate for Nanodispersion (PICN). On 1 December 2014, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for Latanoprost BAK-free eyedrops. While the FDA did not seek any additional information for supporting clinical data, it sought additional information on certain labeling and other deficiencies for processing the NDA. On 4 March 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for ELEPSIA XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). ELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients 12 years of age and older with epilepsy. The product will be manufactured by Sun Pharmaceutical Industries Ltd at its Halol (Gujarat) facility in India. On 9 June 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) and Sun Pharmaceutical Industries Ltd. announced that SPARC has licensed out Xelpros (Latanoprost BAK-free eye drops) to a subsidiary of Sun Pharma for the US market. On 1 August 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) announced that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops. SPARC submitted a response to an earlier CRL it had received from the USFDA, wherein no additional preclinical or clinical data was required. While the USFDA has accepted the clarifications and changes to the labeling, SPARC has now received another CRL from the USFDA seeking minor changes to the proposed labeling. SPARC hopes to address these requirements soon. This product is proposed to be manufactured at Sun Pharmaceutical Industries Ltd (SPIL)'s Halol facility and the USFDA has indicated that a satisfactory resolution of the cGMP deficiencies at this facility is a prerequisite for the final approval of Xelpros. SPARC had recently out-licensed this product to a subsidiary of Sun Pharmaceutical Industries Ltd (SPIL). On 25 September 2015, Sun Pharma Advanced Research Company Ltd. announced that the U.S. Food and Drug Administration (USFDA) has issued a Complete Response letter (CRL) to its New Drug Application (NDA) for Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). SPARC had earlier received a final approval from USFDA in March 2015 for this product and was evaluating several marketing partners for commercialization. However SPARC has now received a CRL from the USFDA rescinding its earlier approval, citing that the compliance status of the manufacturing facility was not acceptable on the date of approval. Elepsia XR is proposed to be manufactured at Sun Pharmaceutical Industries Ltd (SPIL)'s Halol facility. SPIL is working with USFDA in resolving the cGMP deviations at the facility and has taken several corrective measures. On 31 December 2015, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the management expects a possible further delay in the projected royalty income for the company from XELPROS (Latanoprost Ophthalmic Emulsion) and Elepsia XR (Levetiracetam extended-release tablets 1000 mg and 1500 mg). This follows a warning letter to Sun Pharmaceutical Industries Ltd (SPIL) from the USFDA for its facility located at Halol, Gujarat in India. XELPROS and Elepsia XR are proposed to be manufactured at (SPIL)'s Halol facility. The Board of Directors of Sun Pharma Advanced Research Company Ltd. (SPARC) at its meeting held on 5 March 2016 approved rights issue of equity shares in the ratio of 5 equity shares for every 116 equity shares held as on the record date. The rights issue has been priced at Rs 245 per share. The company will raise upto Rs 250 crore from the rights issue. On 18 July 2016, Sun Pharma Advanced Research Company Ltd. (SPARC) and Sun Pharmaceutical Industries Ltd. announced a licensing arrangement for SPARC's ELEPSIA XR (Levetiracetam Extended Release tablets). As per the agreement, SPARC will license ELEPSIA XR (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma for the US market. SPARC will receive an up-front payment of US$10 million from Sun Pharma. It is also eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPSIA XR. On 22 December 2016, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the company has received a Complete Response Letter (CRL) from the USFDA for the New Drug Application (NDA) for Xelpros, Latanoprost BAK-free eyedrops. The CRL references the recent inspection of Sun Pharmaceutical Industries Ltd.'s Halol manufacturing site by USFDA and indicates that satisfactory resolution of the deficiencies identified during the inspection is required before the final approval of Xelpros. There are no requirements of any additional data from USFDA in the CRL. SPARC had out-licensed Xelpros to a subsidiary of Sun Pharmaceutical Industries Ltd. in June 2015. On 19 May 2017, Sun Pharma Advanced Research Company Ltd. (SPARC) informed the stock exchanges that the company has received a Complete Response Letter (CRL) from the USFDA for its New Drug Application (NDA) for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg. On 14 September 2018, Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) announced U.S. Food and Drug Administration (USFDA) approval for the New Drug Application (NDA) of XELPROS (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure (IOP, or pressure inside the eye) in patients with open-angle glaucoma or ocular hypertension. This approval is from Sun Pharma's Halol (Gujarat, India) facility. Sun Pharma in-licensed XELPROS from SPARC in June 2015 and this approval will trigger a milestone payment to SPARC. SPARC is also eligible for milestone payments and royalties on commercialization of XELPROS in the US. In FY 2019-20, Company executed its 1st in-licensing agreement with Bioprojet (France) obtaining exclusive global rights of SCD-044. It also established first commercial partnership with China Medical Systems Ltd., out-licensing commercial rights of five assets (XelprosTM, ElepsiaTM, TaclantisTM, PDP-716 and SDN-037). SPARC's vodobatinib was granted orphan drug designation for treatment of CML. During the year, SPARC also commenced the investigator initiated study of SCC-138 in Lewy Body Dementia. It completed Phase I study of SCD-044. During FY 2021-22, Company progressed on multiple collaborative projects and also acquired exclusive rights for antibody against a unique oncology target from Biomodifying Inc. It licensed the commercialization rights for PDP-716 and SDN-037 to Visiox Pharma, a specialty pharma company focused on ophthalmology. The commercialization of ElepsiaTM XR commenced in 2021. It licensed the global (excluding India and greater China) commercialization rights to Visiox Pharma. On January 06, 2023 the Company had allotted 4,91,92,121 equity shares against the conversion of equal number of warrants issued on preferential basis. Consequent to the said allotment, Shanghvi Finance Private Limited (SFPL) has ceased to be the Company's Holding Company effective from the said date as its percentage shareholding along with its subsidiaries in the Company reduced from 52.07% to 44.18%. During FY23, SPARC along with Visiox completed the NDA submission to the USFDA in August 2023. SezabyTM Commercialization was commenced by Sun Pharma in Jan 2023.

Sun Pharma Advanced Research Company Ltd News Hub

News

Sun Pharma Advanced Research Company to conduct AGM

Sun Pharma Advanced Research Company announced that the 19th Annual General Meeting (AGM) ...

Read more

09 Jul 202412:07

News

SPARC CFO Chetan Rajpara resigns

Rajpara stated that he wants to pursue his ambition and personal goals, which would involv...

Read more

06 Jun 202412:43

News

Sun Pharma Advanced Research Company to hold board meeting

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the ...

Read more

17 May 202416:47

News

Volumes jump at Sun Pharma Advanced Research Company Ltd counter

Jupiter Wagons Ltd, Kotak Mahindra Bank Ltd, Jyothy Labs Ltd, Godfrey Phillips India Ltd a...

Read more

25 Apr 202414:30

News

Sun Pharma Advanced Research Company Ltd Slides 5%

Sun Pharma Advanced Research Company Ltd lost 5% today to trade at Rs 409.55. The S&P BSE ...

Read more

12 Apr 202409:30

News

Sun Pharma Advanced Research Company schedules board meeting

Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the ...

Read more

25 Jan 202411:28

FAQs for dividends of Sun Pharma Advanced Research Company Ltd

What is the current market price of Sun Pharma Advanced Research Company Ltd Ltd as of July 23, 2024?

The current market price of Sun Pharma Advanced Research Company Ltd Ltd stands at 222.0 per share.

What dividend did Sun Pharma Advanced Research Company Ltd declare in the last fiscal year?

In the last fiscal year, Sun Pharma Advanced Research Company Ltd declared a dividend totaling ₹0.0.

What is the most recent dividend declared by Sun Pharma Advanced Research Company Ltd?

Sun Pharma Advanced Research Company Ltd recently declared a dividend of 0.0 in the latest quarter

How many times has Sun Pharma Advanced Research Company Ltd declared dividends in the current fiscal year

Sun Pharma Advanced Research Company Ltd has declared dividends 4 times totaling ₹0 in the current fiscal year (FY2023-2024).

How many times did Sun Pharma Advanced Research Company Ltd declare dividends in the previous fiscal year?

In the previous fiscal year (FY2022-2023), Sun Pharma Advanced Research Company Ltd declared dividends 1 times totaling ₹0.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199